WallStreetZenWallStreetZen

NYSE: NVO
NOVO NORDISK A S Stock Forecast, Predictions & Price Target

Should I buy or sell NVO stock?

Based on 3 analysts offering ratings for NOVO NORDISK A S.
Hold
Strong Buy
1 analysts 33.33%
Buy
0 analysts 0%
Hold
1 analysts 33.33%
Sell
0 analysts 0%
Strong Sell
1 analysts 33.33%

NVO stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
Deutsche Bank
Bottom 45%
45
Strong BuyUpgradesN/AN/A2022-03-16
Liberum
Bottom 43%
43
Strong SellDowngradesN/AN/A2022-01-25
JP Morgan
Top 50%
51
HoldDowngradesN/AN/A2021-12-20

1 of 1

Forecast return on equity

Is NVO forecast to generate an efficient return?
Company
130.86%
Industry
124.21%
Market
32.71%
NVO's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is NVO forecast to generate an efficient return on assets?
Company
44.18%
Industry
20.15%
NVO is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

NVO earnings per share forecast

What is NVO's earnings per share in the next 3 years based on estimates from 5 analysts?
Avg 1 year Forecast
$3.44+8.48%
Avg 2 year Forecast
$4.03+27.09%
Avg 3 year Forecast
$4.59+44.75%
NVO's earnings are forecast to... subscribe to Premium to read more.
Forecast High Earnings Growth Forecast

NVO revenue forecast

What is NVO's revenue in the next 3 years based on estimates from 3 analysts?
Avg 1 year Forecast
$24.8B+12.95%
Avg 2 year Forecast
$27.8B+26.88%
Avg 3 year Forecast
$30.3B+38.21%
NVO's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

NVO earnings growth forecast

How is NVO forecast to perform vs Biotechnology companies and vs the US market?
Company
14.82%
Industry
8.72%
Market
15.78%
NVO's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Industry Forecast
NVO's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Market Forecast
NVO's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Savings Rate Forecast

NVO revenue growth forecast

How is NVO forecast to perform vs Biotechnology companies and vs the US market?
Company
13%
Industry
17.8%
Market
9.29%
NVO's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
NVO's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

NVO vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
NVO$104.05N/AN/AHold
REGN$657.15$731.00+11.24%Buy
VRTX$255.45$265.25+3.84%Buy
MRNA$143.38$241.18+68.21%Buy
BNTX$167.87$291.71+73.77%Buy

NOVO NORDISK A S Stock Forecast FAQ

Is NOVO NORDISK A S Stock a good buy in 2022, according to Wall Street analysts?

The consensus among 3 Wall Street analysts covering (NYSE: NVO) stock is to Hold NVO stock.

Out of 3 analysts, 1 (33.33%) are recommending NVO as a Strong Buy, 0 (0%) are recommending NVO as a Buy, 1 (33.33%) are recommending NVO as a Hold, 0 (0%) are recommending NVO as a Sell, and 1 (33.33%) are recommending NVO as a Strong Sell.

What is NVO's Earnings Per Share (EPS) forecast for 2022-2024?

(NYSE: NVO) NOVO NORDISK A S's current Earnings Per Share (EPS) is $3.04. On average, analysts forecast that NVO's EPS will be $3.44 for 2022, with the lowest EPS forecast at $3.36, and the highest EPS forecast at $3.59. On average, analysts forecast that NVO's EPS will be $4.03 for 2023, with the lowest EPS forecast at $3.72, and the highest EPS forecast at $4.37. In 2024, NVO's EPS is forecast to hit $4.59 (min: $4.33, max: $5.00).

What is NVO's forecast return on equity (ROE) for 2022-2025?

(NYSE: NVO) forecast ROE is 130.86%, which is considered strong.

What is NVO's earnings growth forecast for 2022-2024?

(NYSE: NVO) NOVO NORDISK A S's forecast annual earnings growth rate of 14.82% is forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 8.72%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 15.78%.

NOVO NORDISK A S's earnings in 2022 is $6,949,859,154.On average, 5 Wall Street analysts forecast NVO's earnings for 2022 to be $7,946,400,000, with the lowest NVO earnings forecast at $7,761,600,000, and the highest NVO earnings forecast at $8,292,900,000. On average, 5 Wall Street analysts forecast NVO's earnings for 2023 to be $9,309,300,000, with the lowest NVO earnings forecast at $8,593,200,000, and the highest NVO earnings forecast at $10,094,700,000.

In 2024, NVO is forecast to generate $10,602,900,000 in earnings, with the lowest earnings forecast at $10,002,300,000 and the highest earnings forecast at $11,550,000,000.

What is NVO's revenue growth forecast for 2022-2024?

(NYSE: NVO) NOVO NORDISK A S's forecast annual revenue growth rate of 13% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 17.8%, and while it is forecast to beat the US market's average forecast revenue growth rate of 9.29%.

NOVO NORDISK A S's revenue in 2022 is $20,989,718,309.On average, 3 Wall Street analysts forecast NVO's revenue for 2022 to be $57,180,568,830,000, with the lowest NVO revenue forecast at $55,698,258,000,000, and the highest NVO revenue forecast at $59,341,936,500,000. On average, 3 Wall Street analysts forecast NVO's revenue for 2023 to be $64,235,532,900,000, with the lowest NVO revenue forecast at $62,057,526,300,000, and the highest NVO revenue forecast at $67,278,172,500,000.

In 2024, NVO is forecast to generate $69,968,412,360,000 in revenue, with the lowest revenue forecast at $66,936,916,200,000 and the highest revenue forecast at $74,380,036,500,000.

What is NVO's forecast return on assets (ROA) for 2022-2025?

(NYSE: NVO) forecast ROA is 44.18%, which is higher than the forecast US Biotechnology industry average of 20.15%.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.